
Protagonist raises $22M to revive PTG-100; Paratek's antibiotic shows non-inferiority
→ Protagonist Therapeutics {PTGX}, a tiny public company in Newark, CA, has inked a securities purchase deal totaling $22 million in shares to sort out plans for its former lead program in inflammatory bowel diseases. The new funds will go towards PTG-100, an oral alpha-4-beta-7 integrin antagonist peptide, which was previously in a Phase IIb trial for ulcerative colitis before it was discontinued. Now, the company says its under evaluation for other IBD indications. The biotech is selling 2.75 million shares to investors including BVF Partners and their affiliate. The investors also got five-year warrants to buy up 1.375 million shares at $15 per share.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.